Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EBITDA (2016 - 2025)

IGC Pharma (IGC) has disclosed EBITDA for 16 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • Quarterly EBITDA fell 6.24% to -$1.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$6.5 million through Sep 2025, up 48.44% year-over-year, with the annual reading at -$7.2 million for FY2025, 45.14% up from the prior year.
  • EBITDA for Q3 2025 was -$1.8 million at IGC Pharma, down from -$1.6 million in the prior quarter.
  • The five-year high for EBITDA was -$1.2 million in Q1 2025, with the low at -$6.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$2.8 million, with a median of -$2.4 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 185.41% in 2021, then surged 66.85% in 2024.
  • Over 5 years, EBITDA stood at -$2.3 million in 2021, then dropped by 0.26% to -$2.3 million in 2022, then plummeted by 141.17% to -$5.6 million in 2023, then soared by 66.85% to -$1.8 million in 2024, then increased by 0.38% to -$1.8 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.8 million, -$1.6 million, and -$1.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.